8-K current report · filed Oct 8, 2026

ANGIODYNAMICS INC (ANGO) 8-K Current Report: October 8, 2026

Item 7.01Item EX-99.1Item EX-99.2Item 2.02ANGO overview

Short answer

ANGIODYNAMICS INC (ANGO) filed an 8-K current report with the SEC on October 8, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition). Press release covers fiscal Q1 ended August 31, 2026.

ANGIODYNAMICS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers fiscal Q1 ended August 31, 2026
  • Financial results and management commentary available in Exhibit 99.1
  • Results announcement provides investors the quarter’s operating performance and financial condition update

Item 7.01 · Regulation FD Disclosure

  • Presentation slides cover AngioDynamics’ fiscal first quarter ended August 31, 2026
  • Exhibit 99.2 likely contains quarterly operating results, management commentary and outlook
  • Key investor risks include FDA actions, clinical trials, competition, recalls and product liability
  • Execution risks include supply-chain costs, inflation, distributor relationships and strategic initiatives

Item EX-99.1 · Exhibit EX-99.1

  • Q1 FY2027 revenue $80.9M, up 6.9%, with Med Tech growth 13.2% offsetting largely flat Med Device sales
  • Adjusted EBITDA rose to $5.0M from $2.2M, while adjusted loss narrowed to $0.04 per share from $0.10
  • Gross margin expanded to 59.4%, including $1.2M tariff refunds, indicating underlying margin closer to 57.8%
  • Cash fell to $34.0M after $15.3M operating cash use, though the balance sheet remains debt-free
  • FY2027 guidance reiterated: revenue $336.0M-$341.0M, adjusted EBITDA $13.0M-$16.0M, adjusted EPS loss $0.29-$0.24

Item EX-99.2 · Exhibit EX-99.2

  • Q1 FY2027 revenue $80.9M, up 6.9% year over year, with Med Tech up 13.2% and Med Device up 1.4%
  • Med Tech momentum led by NanoKnife up 29.0%, Auryon up 14.7%, and AlphaVac up 37.4%
  • Profitability improving, adjusted EBITDA $5.0M, despite approximately $15.3M of operating cash use
  • Balance sheet flexibility, $34M cash and zero debt with access to a revolving credit line
  • FY2027 guidance reiterated: revenue $336.0M-$341.0M, adjusted EBITDA $13.0M-$16.0M, adjusted EPS loss ($0.29)-($0.24)
  • CEO transition effective November 2, 2026, with Eric Honroth succeeding Jim Clemmer, who remains executive advisor

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ANGIODYNAMICS INC 8-K filings

Get the next ANGO 8-K as it lands

Follow ANGO for push alerts, or ask the research agent what this filing means.